http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 29 Jun 2026 11:37:53 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26704240.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) has completed its third commercial shipment of 5mg psilocybin capsules to Australia since launching the product in September 2025, according to a company press release.</p><p>The shipment consisted of 1,000 capsules produced at Optimi's GMP-certified facility in Princeton, British Columbia, and exported under authorization from Health Canada. The capsules are prescribed in Australia for treatment-resistant depression, defined as major depression that has not responded to multiple standard antidepressant treatments.</p><p>In Australia, the capsules are dispensed under the Therapeutic Goods Administration's Authorized Prescriber Scheme and are reimbursed by payers including the Department of Veterans' http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26704240.html Mon, 29 Jun 2026 11:37:53 -0400 8BN0 OPTH OPTI http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26704240.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) has completed its third commercial shipment of 5mg psilocybin capsules to Australia since launching the product in September 2025, according to a company press release.</p><p>The shipment consisted of 1,000 capsules produced at Optimi's GMP-certified facility in Princeton, British Columbia, and exported under authorization from Health Canada. The capsules are prescribed in Australia for treatment-resistant depression, defined as major depression that has not responded to multiple standard antidepressant treatments.</p><p>In Australia, the capsules are dispensed under the Therapeutic Goods Administration's Authorized Prescriber Scheme and are reimbursed by payers including the Department of Veterans' http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26704240.html Mon, 29 Jun 2026 11:37:53 -0400 8BN0 OPTH OPTI http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26704240.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) has completed its third commercial shipment of 5mg psilocybin capsules to Australia since launching the product in September 2025, according to a company press release.</p><p>The shipment consisted of 1,000 capsules produced at Optimi's GMP-certified facility in Princeton, British Columbia, and exported under authorization from Health Canada. The capsules are prescribed in Australia for treatment-resistant depression, defined as major depression that has not responded to multiple standard antidepressant treatments.</p><p>In Australia, the capsules are dispensed under the Therapeutic Goods Administration's Authorized Prescriber Scheme and are reimbursed by payers including the Department of Veterans' http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26704240.html Mon, 29 Jun 2026 11:37:53 -0400 8BN0 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html <div class="xn-content"> <p class="prntac"><i>Optimi's 5mg psilocybin capsules are prescribed in <location value="LC/au" idsrc="xmltag.org" >Australia</location> for treatment-resistant depression.<br /></i><i>The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in <chron>September 2025</chron>.</i></p><p><span class="legendSpanClass"><location value="LU/ca.bc.vancvr" idsrc="xmltag.org" >VANCOUVER, BC</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ - <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4721659-1&amp;h=4275734509&amp;u=https%3A%2F%2Fwww.optimihealth.ca%2F&amp;a=Optimi+Health+Corp." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:OPTH" idsrc="xmltag.org" >Optimi Health Corp.</span></a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<b>Company</b>" or "<b>Optimi</b>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to <location value="LC/au" idsrc="xmltag.org" >Australia</location>, marking its third commercial shipment since the <chron>September 2025</chron> http://www.streetinsider.com/PRNewswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26704125.html Mon, 29 Jun 2026 11:13:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26702957.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) has completed its third commercial shipment of 5mg psilocybin capsules to Australia since the product's September 2025 launch, according to a company statement.</p><p>The shipment contained 1,000 capsules produced at Optimi's GMP-certified facility in Princeton, British Columbia, and exported under authorization from Health Canada. The capsules are prescribed in Australia for treatment-resistant depression, a condition defined as major depression that has not responded to multiple standard antidepressant treatments.</p><p>Australia rescheduled psilocybin from a prohibited substance to a controlled medicine for treatment-resistant depression effective July 1, 2023. Optimi's product is being prescribed under the http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26702957.html Mon, 29 Jun 2026 09:01:17 -0400 8BN0 OPTH OPTI http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26702957.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) has completed its third commercial shipment of 5mg psilocybin capsules to Australia since the product's September 2025 launch, according to a company statement.</p><p>The shipment contained 1,000 capsules produced at Optimi's GMP-certified facility in Princeton, British Columbia, and exported under authorization from Health Canada. The capsules are prescribed in Australia for treatment-resistant depression, a condition defined as major depression that has not responded to multiple standard antidepressant treatments.</p><p>Australia rescheduled psilocybin from a prohibited substance to a controlled medicine for treatment-resistant depression effective July 1, 2023. Optimi's product is being prescribed under the http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26702957.html Mon, 29 Jun 2026 09:01:17 -0400 8BN0 OPTH OPTI http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26702957.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) has completed its third commercial shipment of 5mg psilocybin capsules to Australia since the product's September 2025 launch, according to a company statement.</p><p>The shipment contained 1,000 capsules produced at Optimi's GMP-certified facility in Princeton, British Columbia, and exported under authorization from Health Canada. The capsules are prescribed in Australia for treatment-resistant depression, a condition defined as major depression that has not responded to multiple standard antidepressant treatments.</p><p>Australia rescheduled psilocybin from a prohibited substance to a controlled medicine for treatment-resistant depression effective July 1, 2023. Optimi's product is being prescribed under the http://www.streetinsider.com/Corporate+News/Optimi+Health+ships+psilocybin+capsules+to+Australia+in+third+export/26702957.html Mon, 29 Jun 2026 09:01:17 -0400 8BN0 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html <p align="center"><em>Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.</em><br/><em>The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.</em></p> <p align="justify">VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ut93q95vQrkDN4Ktk39tx8UrZ9satGnhPtiqYRfJbaX-8vK_vuryG3Ypth3eTmEgcmjqk8_nbxAmdQi2rUo7IZv21-OUh-csTzGBwRIoN-g=" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “<strong>Company</strong>” or “<strong>Optimi</strong>”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html Mon, 29 Jun 2026 09:00:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html <p align="center"><em>Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.</em><br/><em>The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.</em></p> <p align="justify">VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ut93q95vQrkDN4Ktk39tx8UrZ9satGnhPtiqYRfJbaX-8vK_vuryG3Ypth3eTmEgcmjqk8_nbxAmdQi2rUo7IZv21-OUh-csTzGBwRIoN-g=" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “<strong>Company</strong>” or “<strong>Optimi</strong>”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html Mon, 29 Jun 2026 09:00:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html <p align="center"><em>Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.</em><br/><em>The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.</em></p> <p align="justify">VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ut93q95vQrkDN4Ktk39tx8UrZ9satGnhPtiqYRfJbaX-8vK_vuryG3Ypth3eTmEgcmjqk8_nbxAmdQi2rUo7IZv21-OUh-csTzGBwRIoN-g=" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “<strong>Company</strong>” or “<strong>Optimi</strong>”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html Mon, 29 Jun 2026 09:00:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html <p align="center"><em>Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.</em><br/><em>The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.</em></p> <p align="justify">VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ut93q95vQrkDN4Ktk39tx8UrZ9satGnhPtiqYRfJbaX-8vK_vuryG3Ypth3eTmEgcmjqk8_nbxAmdQi2rUo7IZv21-OUh-csTzGBwRIoN-g=" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “<strong>Company</strong>” or “<strong>Optimi</strong>”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html Mon, 29 Jun 2026 09:00:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html <p align="center"><em>Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.</em><br/><em>The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.</em></p> <p align="justify">VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ut93q95vQrkDN4Ktk39tx8UrZ9satGnhPtiqYRfJbaX-8vK_vuryG3Ypth3eTmEgcmjqk8_nbxAmdQi2rUo7IZv21-OUh-csTzGBwRIoN-g=" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “<strong>Company</strong>” or “<strong>Optimi</strong>”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html Mon, 29 Jun 2026 09:00:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html <p align="center"><em>Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.</em><br/><em>The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.</em></p> <p align="justify">VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ut93q95vQrkDN4Ktk39tx8UrZ9satGnhPtiqYRfJbaX-8vK_vuryG3Ypth3eTmEgcmjqk8_nbxAmdQi2rUo7IZv21-OUh-csTzGBwRIoN-g=" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “<strong>Company</strong>” or “<strong>Optimi</strong>”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html Mon, 29 Jun 2026 09:00:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html <p align="center"><em>Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.</em><br/><em>The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025.</em></p> <p align="justify">VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ut93q95vQrkDN4Ktk39tx8UrZ9satGnhPtiqYRfJbaX-8vK_vuryG3Ypth3eTmEgcmjqk8_nbxAmdQi2rUo7IZv21-OUh-csTzGBwRIoN-g=" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “<strong>Company</strong>” or “<strong>Optimi</strong>”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its 5mg psilocybin capsules.</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Completes+Psilocybin+Export+to+Australia+for+Patients+With+Treatment-Resistant+Depression/26702895.html Mon, 29 Jun 2026 09:00:00 -0400 8BN0 A.17150087 O.34929518 O.53098441 OPTH OPTI